Retrospective study comparing healthcare costs and utilization between commercially insured patients with type 2 diabetes mellitus who are newly initiating exenatide once weekly or liraglutide in the United States

References

• Centers for Disease Control and Prevention. National Diabetes Statistics Report, 2014. Available at: http://www.cdc.gov/diabetes/pubs/statsreport14/national-diabetes-report-web.pdf [Last accessed 26 June 2014]
   Google Scholar
• American Diabetes Association. Economic costs of diabetes in the U.S. in 2012. Diabetes Care 2013;36:1033-46
   PubMed Web of Science ®Google Scholar
• Dall TM, Mann SE, Zhang Y, et al. Distinguishing the economic costs associated with type 1 and type 2 diabetes. Popul Health Manag 2009;12:103-10
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Standards of medical care in diabetes – 2014. Diabetes Care 2014;37(Suppl 1):S14-80
   PubMed Web of Science ®Google Scholar
• Garber AJ, Abrahamson MJ, Barzilay JI, et al. American Association of Clinical Edocrinologists Comprehensive Diabetes Management Algorithm 2013 Consensus Statement. Endocr Pract 2013;19(Suppl 2):1-48
   Google Scholar
• Bydureon [package insert]. San Diego, CA: Amylin Pharmaceuticals Inc., 2012
   Google Scholar
• Byetta [package insert]. San Diego, CA: Amylin Pharmaceuticals Inc., 2011
   Google Scholar
• Victoza [package insert]. Plainsboro, NJ: Novo Nordisk, 2013
   Google Scholar
• Tanzeum [package insert]. Wilmington, DE: GlaxoSmithKline LLC, 2014
   Google Scholar
• Trulicity [package insert]. Indianapolis, IA: Eli Lilly & Co, 2014
   Google Scholar
• What payers want: viewing payers as customers. Deloitte Life Sciences, 2009. Available at: http://www.deloitte.com/assets/Dcom-UnitedStates/Local%20Assets/Documents/us_lshc_WhatPayersWant_091109.pdf [Last accessed 22 August 2013]
   Google Scholar
• Managed Care. Payers Step in With ‘Real-World’ Comparative Effectiveness Research. 2011. Available at: http://www.managedcaremag.com/archives/1106/1106.cer.html [Last accessed 22 August 2013]
   Google Scholar
• Johnston SS, Nguyen H, Felber E, et al. Retrospective study of adherence to glucagon-like peptide-1 receptor agonist therapy in patients with type 2 diabetes mellitus in the United States. Adv Ther 2014;31:1119-33
   Google Scholar
• Saunders B, Nguyen H, Kalsekar I. Real-world comparative effectiveness of exenatide once weekly and liraglutide in patients with type 2 diabetes mellitus. Presented at the American Diabetes Association (ADA) 74th Scientific Sessions, 13–17 June 2014, San Francisco, CA, USA
   Google Scholar
• Pelletier EM, Pawaskar M, Smith PJ, et al. Economic outcomes of exenatide vs liraglutide in type 2 diabetes patients in the United States: results from a retrospective claims database analysis. J Med Econ 2012;15:1039-50
   PubMedGoogle Scholar
• DeKoven M, Lee WC, Bouchard J, et al. Real-world cost-effectiveness: lower cost of treating patients to glycemic goal with liraglutide versus exenatide. Adv Ther 2014;31:202-16
   PubMed Web of Science ®Google Scholar
• Asche C, LaFleur J, Conner C. A review of diabetes treatment adherence and the association with clinical and economic outcomes. Clin Ther 2011;33:74-109
   PubMed Web of Science ®Google Scholar
• Wild H. The economic rationale for adherence in the treatment of type 2 diabetes mellitus. Am J Manag Care 2012;18(3 Suppl):S43-8
   Google Scholar
• Salas M, Hughes D, Zuluaga A, et al. Costs of medication nonadherence in patients with diabetes mellitus: a systematic review and critical analysis of the literature. Value Health 2009;12:915-22
   PubMed Web of Science ®Google Scholar
• Truven Health Analytics. MarketScan Bibliography. Available at: http://marketscan.truvenhealth.com/marketscanuniversity/publications/2012%20Truven%20Health%20MarketScan%20Bibliography.pdf [Last accessed 20 June 2014]
   Google Scholar
• Kleinman LC, Norton EC. What’s the risk? A simple approach for estimating adjusted risk measures from nonlinear models including logistic regression. Health Serv Res 2009;44:288-302
   PubMed Web of Science ®Google Scholar
• Rubin RR. Adherence to pharmacologic therapy in patients with type 2 diabetes mellitus. Am J Med 2005;118(Suppl 5A):27-34S
   PubMed Web of Science ®Google Scholar
• Zhang L, Zakharyan A, Stockl KM, et al. Mail-order pharmacy use and medication adherence among Medicare Part D beneficiaries with diabetes. J Med Econ 2011;14:562-7
   PubMedGoogle Scholar
• Dezii CM, Kawabata H, Tran M. Effects of once-daily and twice-daily dosing on adherence with prescribed glipizide oral therapy for type 2 diabetes. South Med J 2002;95:68-71
   PubMed Web of Science ®Google Scholar
• Ingersoll KS, Cohen J. The impact of medication regimen factors on adherence to chronic treatment: a review of literature. J Behav Med 2008;31:213-24
   PubMed Web of Science ®Google Scholar
• Melikian C, White TJ, Vanderplas A, et al. Adherence to oral antidiabetic therapy in a managed care organization: a comparison of monotherapy, combination therapy, and fixed-dose combination therapy. Clin Ther 2002;24:460-7
   PubMed Web of Science ®Google Scholar
• Pollack M, Chastek B, Williams SA, et al. Impact of treatment complexity on adherence and glycemic control: an analysis of oral antidiabetic agents. J Clin Outcomes Manage 2010;17:257-65
   Google Scholar
• Hauber B, Nguyen H, Posner J, et al. Patient preferences for frequency of glucagon-like peptide-1 receptor agonist (GLP-1RA) injections in the treatment of type 2 diabetes. Presented at the ISPOR 19th Annual International Meeting, 31 May–4 June 2014, Montreal, QC, Canada
   Google Scholar
• Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005;353:487-97
   PubMed Web of Science ®Google Scholar
• Ho PM, Rumsfeld JS, Masoudi FA, et al. Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. Arch Intern Med 2006;166:1836-41
   PubMed Web of Science ®Google Scholar
• Lau DT, Nau DP. Oral antihyperglycemic medication nonadherence and subsequent hospitalization among individuals with type 2 diabetes. Diabetes Care 2004;27:2149-53
   PubMed Web of Science ®Google Scholar
• Karve S, Cleves MA, Helm M, et al. Good and poor adherence: optimal cut-point for adherence measures using administrative claims data. Curr Med Res Opin 2009;25:2303-10
   PubMed Web of Science ®Google Scholar
• Scott DA, Boye KS, Timlin L, et al. A network meta-analysis to compare glycaemic control in patients with type 2 diabetes treated with exenatide once weekly or liraglutide once daily in comparison with insulin glargine, exenatide twice daily or placebo. Diabetes Obes Metab 2013;15:213-23
   PubMed Web of Science ®Google Scholar
• Menzin J, Korn JR, Cohen J, et al. Relationship between glycemic control and diabetes-related hospital costs in patients with type 1 or type 2 diabetes mellitus. J Manag Care Pharm 2010;16:264-75
   PubMed Web of Science ®Google Scholar
• Buse JB, Nauck M, Forst T, et al. Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. Lancet 2013;381:117-24
   PubMed Web of Science ®Google Scholar